Literature DB >> 16344491

Infectious origin of the antiphospholipid syndrome.

Y Shoenfeld, M Blank, R Cervera, J Font, E Raschi, P-L Meroni.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16344491      PMCID： PMC1797971          DOI： 10.1136/ard.2005.045443

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  34 in total

1.  The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome--molecular mimicry?

Authors:  R A Asherson; Y Shoenfeld
Journal:  J Rheumatol       Date:  2000-01       Impact factor: 4.666

2.  Disappearance of antiphospholipid antibodies syndrome after Helicobacter pylori eradication.

Authors:  V Cicconi; E Carloni; F Franceschi; R Nocente; N G Silveri; R Manna; S Servidei; A R Bentivoglio; A Gasbarrini; G Gasbarrini
Journal:  Am J Med       Date:  2001-08       Impact factor: 4.965

3.  Catastrophic antiphospholipid syndrome: remission following leg amputation in 2 cases.

Authors:  H Amital; Y Levy; C Davidson; I Lundberg; A Harju; Y Kosach; R A Asherson; Y Shoenfeld
Journal:  Semin Arthritis Rheum       Date:  2001-10       Impact factor: 5.532

4.  Systemic antiphospholipid syndrome.

Authors:  Y Shoenfeld
Journal:  Lupus       Date:  2003       Impact factor: 2.911

Review 5.  Endothelial cell activation by antiphospholipid antibodies.

Authors:  P L Meroni; E Raschi; C Testoni; M O Borghi
Journal:  Clin Immunol       Date:  2004-08       Impact factor: 3.969

Review 6.  Beta-2-glycoprotein-I, infections, antiphospholipid syndrome and therapeutic considerations.

Authors:  Miri Blank; Yehuda Shoenfeld
Journal:  Clin Immunol       Date:  2004-08       Impact factor: 3.969

Review 7.  Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines.

Authors:  R A Asherson; R Cervera; P G de Groot; D Erkan; M C Boffa; J C Piette; M A Khamashta; Y Shoenfeld
Journal:  Lupus       Date:  2003       Impact factor: 2.911

8.  Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndrome.

Authors:  Y Shoenfeld; I Krause; F Kvapil; J Sulkes; S Lev; P von Landenberg; J Font; J Zaech; R Cervera; J C Piette; M C Boffa; M A Khamashta; M L Bertolaccini; G R V Hughes; P Youinou; P L Meroni; V Pengo; J D Alves; A Tincani; G Szegedi; G Lakos; G Sturfelt; A Jönsen; T Koike; M Sanmarco; A Ruffatti; Z Ulcova-Gallova; S Praprotnik; B Rozman; M Lorber; V B Vriezman; M Blank
Journal:  J Clin Immunol       Date:  2003-09       Impact factor: 8.317

9.  A peptide that shares similarity with bacterial antigens reverses thrombogenic properties of antiphospholipid antibodies in vivo.

Authors:  Silvia S Pierangeli; Miri Blank; Xiaowei Liu; Ricardo Espinola; Mati Fridkin; Mariano Vega Ostertag; Karen Roye-Green; E Nigel Harris; Yehuda Shoenfeld
Journal:  J Autoimmun       Date:  2004-05       Impact factor: 7.094

Review 10.  Antiphospholipid syndrome infectious origin.

Authors:  M Blank; R A Asherson; R Cervera; Y Shoenfeld
Journal:  J Clin Immunol       Date:  2004-01       Impact factor: 8.542
View more
  44 in total

Review 1.  From molecular mimicry to cross-reactivity or pathogen expansion? A hypothesis.

Authors:  Alexander P Rozin
Journal:  Clin Rheumatol       Date:  2006-06-29       Impact factor: 2.980

Review 2.  Clinical and laboratory features of the catastrophic antiphospholipid syndrome.

Authors:  Ljudmila Stojanovich; Dragomir Marisavljevic; Jozef Rovensky; Aleksandra Djokovich; Darina Kozáková; Nikola Milinic
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 3.  Antiphospholipid antibodies in rheumatoid arthritis: identifying the dominoes.

Authors:  Debbie A Gladd; Ewa Olech
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

4.  Adjuvant dependence of APS pathology-related low-affinity antibodies during secondary immune response to tetanus toxoid in BALB/c mice.

Authors:  Irena Zivković; Vladimir Petrušić; Rajna Dimitrijević; Marijana Stojanović; Ljiljana Dimitrijević
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

Review 5.  Surfactant Lipids at the Host-Environment Interface. Metabolic Sensors, Suppressors, and Effectors of Inflammatory Lung Disease.

Authors:  Michael B Fessler; Ross S Summer
Journal:  Am J Respir Cell Mol Biol       Date:  2016-05       Impact factor: 6.914

6.  Lipid peroxidation as risk factor for endothelial dysfunction in antiphospholipid syndrome patients.

Authors:  Natasa Stanisavljevic; L Stojanovich; D Marisavljevic; A Djokovic; V Dopsaj; J Kotur-Stevuljevic; J Martinovic; L Memon; S Radovanovic; B Todic; D Lisulov
Journal:  Clin Rheumatol       Date:  2016-08-25       Impact factor: 2.980

7.  Antiphospholipid antibodies and multiple organ failure in critically ill cancer patients.

Authors:  Jorge I F Salluh; Márcio Soares; Ernesto De Meis
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

Review 8.  Antiphospholipid syndrome and vascular ischemic (occlusive) diseases: an overview.

Authors:  Penka A Atanassova
Journal:  Yonsei Med J       Date:  2007-12-31       Impact factor: 2.759

Review 9.  Systematic review of case reports of antiphospholipid syndrome following infection.

Authors:  N Abdel-Wahab; M A Lopez-Olivo; G P Pinto-Patarroyo; M E Suarez-Almazor
Journal:  Lupus       Date:  2016-04-07       Impact factor: 2.911

10.  Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up.

Authors:  Tunde Tarr; Gabriella Lakos; Harjit Pal Bhattoa; Pal Soltesz; Yehuda Shoenfeld; Gyula Szegedi; Emese Kiss
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.